Liquidia Q1 net loss widens to $40.9M; YUTREPIA legal barriers removed

Liquidia Corp

2024-Q1 EPS reported -$0.54 revenue$2,972,000

Net loss $40.9M ($0.54/share) vs $11.7M ($0.18) in Q1 2023; revenue fell 33% to $3.0M on lower Treprostinil Injection sales.
Cash $157.9M after $100M gross proceeds from common stock private placement and RIFA fourth amendment in January 2024.
G&A expenses surged 160% to $20.2M, driven by $3.1M higher litigation costs and $5.9M personnel rise.
All legal barriers to FDA approval of YUTREPIA removed; awaiting ruling on preliminary injunction in new UTHR patent suit.
ASCENT study of YUTREPIA in PH-ILD enrolling; L606 liposomal treprostinil data to be presented at ATS 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.